Medivir Interim Report 1 Jan-30 Sep 2003

INTERIM REPORT, 1 January - 30 September 2003 In July, Medivir entered a licensing agreement with Boehringer Ingelheim (BI) on MIV-310. · CCS group divested to the Segulah II L.P. investment fund as of 1 July 2003 for SEK 210 m. · In July, Medivir entered a licensing agreement with the Population Council on MIV-150. Medivir's stock has been quoted on the Stockholm Exchange's Attract 40 list since 1 July. · Medivir's net sales were SEK 148.2 (208.7)m, profit after tax stood at SEK 2.3 (-26.7)m and earnings per share amounted to SEK 0.27 (-3.16). FOR MORE INFORMATION, PLEASE CONTACT: Rein Piir, CFO and VP IR, +46 8 5468 3123 or +46 (0)70 853 7292 ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full report The full report

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.